Case report of hypoglycemic coma caused by a falsified semaglutide product highlights the dangerous consequences of counterfeit GLP-1 drug products entering the market.
Key findingCase report of hypoglycemic coma caused by a falsified semaglutide product highlights the dangerous
What the researchers found
Case report of hypoglycemic coma caused by a falsified semaglutide product highlights the dangerous consequences of counterfeit GLP-1 drug products entering the market.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
31-year-old woman admitted with hypoglycemic coma after using a falsified semaglutide product.
How the study worked
In publication.
Who was studied
31-year-old woman who used a counterfeit semaglutide product for weight loss
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Hypoglycaemic coma induced by a falsified semaglutide product: a case report.
European journal of hospital pharmacy : science and practice
Citation
Antonacci, Giulia; Bortignon, Erika; Bolognesi, Massimo; Piano, Salvatore Silvio; Cadore, Alessandro; Camuffo, Laura; Venturini, Francesca; Faoro, Sonia; Favretto, Donata; Romano, Antonietta; Mengato, Daniele. (2025). Hypoglycaemic coma induced by a falsified semaglutide product: a case report.. European journal of hospital pharmacy : science and practice. https://doi.org/10.1136/ejhpharm-2025-004656